InsidersTradesSigma
Total declarations
Companies
▲ Purchases (5 ops.)
▼ Sales (0 ops.)
Insider track record
CEODisclosed buys
5
Disclosed sells
0
Not enough buy signals with a settled T+90 horizon to measure a track record yet.
Signal history
Explore the complete record of transactions filed by Bischofberger Norbert W, Chairman & CEO. Officer active across 2 companies, notably Kronos Bio, Inc.. Cumulatively, 11 disclosures have been published. Split: 5 buys · 0 sell. Total volume traded: €3.1m. Activity tracked since 6 December 2021. The latest transaction was filed on 27 May 2026 (Attribution). Regulator: SEC (Form 4). The full history is accessible without signup.
Companies and markets linked to Bischofberger Norbert W
Open company profiles for insider transactions, fundamentals and analyst consensus when available.
Declarations11 total
8,000 shares0Common StockSEC:0001628280-26-038961:0
10,802,138 shares@ US$0.5763.6% of flowCommon StockSEC:0001415889-25-017836:0
10,667 shares0Common StockSEC:0001628280-25-030078:0
8,000 shares0Common StockSEC:0001628280-25-028888:0
410,848 shares@ US$1.165513.9% of flowCommon StockSEC:0001415889-24-018703:0
Canonical exit: 25 Sept 2024 (T+90)
1,378,901 shares@ US$0.876434.9% of flowCommon StockSEC:0001415889-24-016563:0
Canonical exit: 8 Sept 2024 (T+90)
16,000 shares0Common StockSEC:0001628280-24-025997:0
270,339 shares0Common StockSEC:0001415889-24-004262:0
1,370,688 shares@ US$0.804531.5% of flowCommon StockSEC:0001209191-23-055826:0
Canonical exit: 13 Feb 2024 (T+90)
90,931 shares@ US$3.83293.9% of flowCommon StockSEC:0001209191-22-030688:0
Canonical exit: 15 Aug 2022 (T+90)
14,356 shares@ US$12.0851.8% of flowCommon StockSEC:0001209191-21-068594:0
Canonical exit: 6 Mar 2022 (T+90)
11 of 11 declarations
About Bischofberger Norbert W
BISCHOFBERGER NORBERT W is Chief Executive Officer and Chairman. He has 11 filings in total. Across the 11 most recent sampled filings, they cover the period from 2021-12-08 to 2026-05-28, with EUR 3,067,410 of purchases and EUR 0 of sales, and the most common transaction nature is Acquisition. His filings concern Kronos Bio, Inc. and Vir Biotechnology, Inc., with several filings for Kronos Bio, Inc.
